<DOC>
	<DOCNO>NCT01611909</DOCNO>
	<brief_summary>This study aim investigate efficacy safety topical p-menthane-3,8-diol ( PMD ) -rich Corymbia Citriodora oil ( Citriodiol速 ) child impetigo . Citriodiol速 already know effective insect repellent safe topical application . The investigator also find laboratory bactericidal Staphylococcus aureus , bacteria responsible cause impetigo . Parents always search natural alternative antibiotic ( current gold standard treatment impetigo ) , investigator believe Citriodiol速 could provide possible alternative .</brief_summary>
	<brief_title>Citriodiol速 Impetigo</brief_title>
	<detailed_description>The extract lemon eucalyptus , common plant , since 1970s used commercial insect repellent product . Recently , show lemon eucalyptus potent anti-bacterial anti-fungal effect assist treatment inflammatory condition impetigo . Our aim investigate investigate safety efficacy product treatment Impetigo . A randomised , double-blinded , three-armed pilot study , involve total 30 patient recruited dermatology outpatient department clinic Royal North Shore hospital study . These patient age 12 month 12 year clinical diagnosis Impetigo . The three treatment group include 2 % 5 % topical p-menthane-3,8-diol ( extracted lemon eucalyptus ) topical Mupirocin arm , apply topically twice day till resolution symptom . Follow-up occur weekly resolution symptom , expect within 2 week . Photographs , disease severity assessment lesional swab culture take recruitment progress .</detailed_description>
	<mesh_term>Impetigo</mesh_term>
	<mesh_term>Terpin</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>age 12 month 12 year dermatologistconfirmed impetigo write informed consent provide parent impetigo require oral/systemic therapy diagnosis another form staphylococcal streptococcal disease ( eg , cellulitis , erysipelas , abscess ) serious local infection ( eg , cellulitis , abscess , wound infection ) systemic infection oral topical antibiotic know allergy topical insect repellent patient receive systemic corticosteroid , immunosuppressive agent , radiation therapy , chemotherapy within 1 month prior entry study history clinically significant poorly control cardiac , haematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , psychiatric , and/or major disease determine investigator current enrollment trial investigational drug within 30 day prior study drug administration unspecified reason , opinion investigator make patient unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>p-menthane-3,8-diol oil extract</keyword>
	<keyword>topical therapy</keyword>
</DOC>